Expand NNVC Menu
NNVC MENU

NNVC Latest Press Releases

-- October 20, 2026 --

NanoViricides' Revolutionary Broad-Spectrum Drug Candidate NV-387 Has Successfully Demonstrated Excellent Indications for Safety and Toxicology in a Juvenile Mouse Pups Animal Study, Paving the Way for Pediatric Use in Clinical Trials ACCESS Newswire 8:45 AM

-- October 13, 2026 --

Phase II Clinical Trial of NV-387 Oral Gummies as Treatment of Ebola Progressing Well, Says NanoViricides ACCESS Newswire 8:45 AM

-- October 6, 2026 --

NanoViricides Presenting at NIBA's 153rd Investment Conference in Fort Lauderdale, FL October 7, 2026 ACCESS Newswire 8:45 AM

-- October 5, 2026 --

NanoViricides Provides Additional Details on the Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola as the Outbreak Continues to Expand and Has Taken Over 4,000 Lives ACCESS Newswire 8:45 AM

-- September 29, 2026 --

NanoViricides, Inc. Has Filed its Annual Report: Broad-spectrum Antiviral NV-387 Is In Phase II Clinical Trials ACCESS Newswire 8:45 AM

-- September 28, 2026 --

Clinical Trial of the Oral Drug NV-387 to Treat Ebola Has Started Enrollment and Dosing of Patients Last Week (on or about September 23rd), Says NanoViricides ACCESS Newswire 8:45 AM

-- September 23, 2026 --

Phase II Clinical Trial of NV-387 as a Treatment for Monkeypox (MPox) Has Begun in DRC, Announces NanoViricides ACCESS Newswire 8:30 AM

-- September 15, 2026 --

Clinical Trial of the Oral Drug NV-387 to Treat Ebola to Start Next Week, Hoping to Reduce Fatalities and Spread, As the Largest Ebola Outbreak is Expanding in ?DR Congo with 48% Crude Fatality Rate, Says NanoViricides ACCESS Newswire 9:25 AM
A $57 Billion Antiviral Market Is Taking Shape As The World Prepares For The Next Viral Threat Globe Newswire 9:00 AM

-- September 8, 2026 --

Clinical Trial for an Oral Drug to Treat Ebola is Registered in the Pan African Clinical Trials Database and is Ready to Go, As the Largest Ebola Outbreak Continues to Expand in DR Congo ACCESS Newswire 8:30 AM

-- August 31, 2026 --

While Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles ACCESS Newswire 8:30 AM

-- August 18, 2026 --

The Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo to Fight the Current Largest Ever and Expanding Ebola Outbreak to Begin Soon ACCESS Newswire 8:30 AM

-- August 10, 2026 --

NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak ACCESS Newswire 8:30 AM

-- July 28, 2026 --

NanoViricides Awaits Approval from DR Congo Regulatory Agency for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola, Financing Completed to Support the Trial ACCESS Newswire 8:30 AM

-- July 24, 2026 --

NanoViricides Announces Pricing of ~$3.8 Million Registered Direct Offering ACCESS Newswire 8:00 AM

-- July 22, 2026 --

As Ebola Death Toll Surpasses 930 Within Two Months, NanoViricides Has Applied to the DR Congo Regulatory Agency for Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola ACCESS Newswire 8:30 AM

-- July 13, 2026 --

As Ebola Spreads in Two More Provinces, NanoViricides Has Received National Ethics Committee Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in Congo ACCESS Newswire 9:27 AM

-- July 8, 2026 --

Research Analyst Report on NanoViricides Rates Company "Outperform"; Separately, A "Fireside Chat" Interview of the Company's President Dr. Anil Diwan Hosted by Mr. Dave Donlin was Published by StockInvestor Daily ACCESS Newswire 8:30 AM

-- July 6, 2026 --

As the Ebola Epidemic Spreads, NanoViricides Advances Towards a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo ACCESS Newswire 8:30 AM

-- June 29, 2026 --

US FDA Has Granted A "Rare Pediatric Disease Drug" Designation for NV-387 As A Treatment for Measles - Enables Priority Review Voucher ACCESS Newswire 8:30 AM

-- June 22, 2026 --

NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo ACCESS Newswire 9:30 AM

-- June 15, 2026 --

As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of Ebola - NanoViricides Proposal is Approved by the Pillar Committee in DR Congo ACCESS Newswire 8:30 AM

-- June 8, 2026 --

As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment - with Superior Oral Administration and Escape Resistance Features Over Antibodies ACCESS Newswire 8:30 AM

-- May 26, 2026 --

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides ACCESS Newswire 8:31 AM
Market Data Delayed 15 Minutes